ASCENT COPD Study

Summary: 

This study will be a double-blind, randomized, placebo-controlled, parallel-group study to evaluate the effect of Aclidinium bromide on the cardiovascular safety and COPD exacerbations in patients with moderate to very severe COPD, as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (GOLD, 2011). The Objectives of this study are to assess the safety of Aclidinium bromide on major adverse cardiovascular events (MACE), to assess the overall safety of Aclidinium bromide and to assess whether Aclidinium bromide reduces moderate or severe COPD exacerbations.

Sponsor: 

Forest Pharmaceuticals

Research Specialties: 

Pulmonary

Link: 

Clinicaltrials.gov